Abstract library

94 results for "Patel".
#1150 Platelet Serotonin But Not Dopamine Concentrations Are Lower in Pancreatic Neuroendocrine Tumor and Renal Cell Carcinoma Patients Compared to Healthy Individuals.
Introduction: Platelets carry VEGF-A, serotonin and dopamine. Serotonin stimulates and dopamine inhibits tumor angiogenesis. We hypothesized that platelets are activated in tumor vasculature and release angiogenic factors, resulting in lower platelet serotonin and dopamine.
Conference: 12th Annual ENETS Conference (2015)
Category: Basic Science - mTOR and other pathways, signalling, receptors
Presenting Author: Marloes Peters
#1917 Clinical Correlates of Discrepant Results of Chromogranin a versus Serotonin Markers in Patients with Neuroendocrine Tumors
Introduction: Neuroendocrine tumors lead to elevated chromogranin A levels and elevated serotonin markers (urinary 5HIAA and platelet serotonin). These markers are employed for diagnosis and monitoring.
Conference: 14th Annual ENETS conference (2017)
Category: Biomarkers
Presenting Author: Dr Wim Meijer
Authors: Meijer W, Bruikman C, Beukeveld G, ...
#612 Serotonin in Blood: Assessment of its Origin by Concomitant Determination of β-Thromboglobulin (platelets) and Chromogranin A (enterochromaffin cells)
Introduction: Serotonin is produced in enterochromaffin (EC) cells, taken up and stored in platelets and released during platelet activation. Measurement of platelet-poor plasma serotonin is difficult, mainly due to platelet activation during blood sampling.
Conference: 10th Annual ENETS Conference (2013)
Category: Biomarkers
Presenting Author: Øyvind Hauso
#15 Gastroduodenal ulceration associated with radioembolization for the treatment of liver malignancies, a newly observed complication: Institutional experience and review of the literature
Introduction: Microsphere radioembolization is a method of delivering radiation therapy directly to tumors, thereby minimizing toxicity to adjacent structures. Despite the relatively high precision of this modality, numerous adverse effects have been recognized. One particularly untoward complication is the development of severe gastroduodenal ulceration.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr. Steven Naymagon
#28 Prognostic Clinicopathologic Factors in Longitudinally Followed Patients with Metastatic Small Bowel Carcinoid
Introduction: Neuroendocrine tumors demonstrate heterogeneous behavior based upon site of origin and specific histology. Even after controlling for anatomic location, disease stage and histologic grade, registry studies show persistent diversity of outcome in patients with midgut carcinoid.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Mr. Thomas Curran
#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR
Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Larry K Kvols
#148 Near-complete regression of liver metastatic lesions in a patient with advanced pancreatic gastrinoma in response to somatostatin analogue therapy following cytoreductive surgery
Introduction: Although the majority of pancreatic NETs present with hepatic metastases, surgery with curative intent should be the first consideration. Cytoreductive surgery by resection of primary and secondary deposits may be of value in achieving local or endocrine symptoms control.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: Dr Dorota Dworakowska
Authors: Dworakowska D, Whyte M, Kane P, Patel A, ...
#160 The role of T-type calcium channels in medullary thyroid carcinoma (MTC): T-type calcium channel blockers inhibit hormone secretion and induce apoptotic cell death in a human MTC cell line
Introduction: Medullary thyroid carcinoma (MTC) accounts for approximately 5-10% of thyroid cancers. In the case of tumors limited to the thyroid gland, the prognosis is generally favorable, whereas 5-year survival averages only 40% in patients with metastatic disease. In these patients, conventional chemotherapy only occasionally leads to a complete response and partial responses are observed in less than 30% of the cases. Therefore, intense efforts are currently directed toward the identification of new druggable targets for the treatment of this devastating disease.
Conference: 7th Annual ENETS Conference (2010)
Category: Basic
Presenting Author: Dr Rosario Pivonello
#265 A Novel PKCßII Inhibitor Induces Antiproliferative Effects in Human Pancreatic Neuroendocrine Tumor Cells
Introduction: Deregulation of the protein kinase C (PKC) signaling pathway has been implicated in tumor progression.
Conference: 8th Annual ENETS Conference (2011)
Category: Basic
Presenting Author: MD Maria Chiara Zatelli
#266 Everolimus Reduces Cell Viability in Selected Human Medullary Thyroid Carcinoma Primary Cultures
Introduction: It has been demonstrated that everolimus, an mTOR inhibitor, has a potent anti-proliferative effect in a human Medullary Thyroid Carcinoma (MTC) cell line, TT, and in two human MTC primary cultures.
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: MD Maria Chiara Zatelli
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.